

Search for Market Research Reports  

[Home](#) > [Category](#) > [Medical Device](#) > Optical Molecular Imaging 2010

 日本語    한국어    中文

**Category**
**Medical Device**
[Cardiovascular Control Equipment](#)
[Catheter Equipment](#)
[CT and MRI and X ray](#)
[Dental Equipment](#)
[Disposable Medical Device](#)
[Endoscopy Equipment](#)
[Healthcare IT](#)
[In Vitro Diagnostics Equipment](#)
[Medical Imaging](#)
[Molecular Imaging/Agents](#)
[Nuclear Medical](#)
[Ophthalmic Equipment](#)
[Orthopedic](#)
[Patient Monitoring](#)
[Ultra Sound](#)
[Wound Care](#)
[View All Categories](#)


Looking for Surgery Volume Reports?



Point of Care Testing Market Research Report



Interested in Conferences?  
 Learning Exhibiting Networking

**Market Research Report**
**Optical Molecular Imaging 2010**

 Published by [Strategies Unlimited](#)

Published 2010/01      Content info 70 Pages

Product code 107992

 Price From **US \$ 4950**      
 Hard Copy **US \$ 4950**

[How to Order?](#)
**Contact us**
**+1 - 860 - 674 - 8796**

Toll Free (US)

**+1 - 866 - 353 - 3335**

**Delivery Time**
**PDF by E-Mail**

Approx. 1-2 business days

**Hard Copy/CD-ROM**

Approx. 3-4 business days

If you need expedited delivery, please call us.

         
**Table of Contents**
**1. EXECUTIVE SUMMARY**
**2. INTRODUCTION**

- 2.1 Methodology
- 2.2 Overview of the Optical Molecular Imaging Market

**3. OPTICAL MOLECULAR IMAGING DEFINED**

- 3.1 What is In Vivo Optical Molecular Imaging?
- 3.2 Fluorescence
  - 3.2.1 Basic Hardware
  - 3.2.2 Fluorescent Molecules
  - 3.2.3 Challenges
- 3.3 Bioluminescence
  - 3.3.1 Basic Hardware
  - 3.3.2 Luciferase Enzymes
  - 3.3.3 Challenges
- 3.4 Extending the Reach of OMI
  - 3.4.1 Multispectral Imaging and Spectral Unmixing
  - 3.4.2 Fluorescence Molecular Tomography
  - 3.4.3 Near-Infrared Fluorescence
  - 3.4.4 Light Delivery
  - 3.4.5 Optical Molecular Imaging Coupled with Existing Imaging Modalities
  - 3.4.6 Emerging Technologies: Photoacoustic Systems
  - 3.4.7 Conclusion

**4. APPLICATIONS OF OPTICAL MOLECULAR IMAGING**

- 4.1 Preclinical Applications
  - 4.1.1 Small Animal Studies for Drug Development
  - 4.1.2 Small Animal Studies for Disease Monitoring
- 4.2 Clinical Applications
  - 4.2.1 Oncology Surgery
  - 4.2.2 Breast Cancer Diagnosis
  - 4.2.3 Mapping the Human Lymphatic System
  - 4.2.4 Clinical Trials

**5. OPTICAL MOLECULAR IMAGING MARKET FORECAST**

- 5.1 Forecast Summary
- 5.2 Overall OMI Market Share

**Related Report**
[Advances in Molecular Imaging: Companies and technologies that are driving change](#)
[Medical Imaging Reagents and Analysis Equipment](#)
[Imaging Agents - A Worldwide Market Review](#)
[Imaging Agents](#)
[Contrast Agents for Medical Imaging](#)

- 5.3 Preclinical Opportunities
- 5.4 Clinical Opportunities
  - 5.4.1 Hospital Settings - Oncology Surgery
  - 5.4.2 Doctors' Offices - Diagnostics and Therapy Monitoring
  - 5.4.3 Breast Cancer Imaging and Diagnosis
  - 5.4.4 Colorectal Cancer Diagnosis
- 5.5 A Word About Imaging Agents
- 5.6 Factors Influencing the Forecast
  - 5.6.1 FDA Approval
  - 5.6.2 Intellectual Property Rights
  - 5.6.3 Insurance Reimbursement
- 5.7 Final Forecast Thoughts

## 6. PROFILES OF LEADING COMPANIES AND PRODUCTS

- 6.1 Advanced Research Technologies Inc.
- 6.2 AntiCancer Inc.
- 6.3 Caliper LifeSciences
- 6.4 Cambridge Research and Instrumentation (CRI)
- 6.5 Carestream Molecular Imaging
- 6.6 Fluoptics
- 6.7 GE Healthcare
- 6.8 INDEC BioSystems, Inc.
- 6.9 LI-COR Biosciences
- 6.10 O2view
- 6.11 Spectros Corporation
- 6.12 VisEn Medical Inc.
- 6.13 Preclinical Imaging Systems and Agents
- 6.14 Timeline

## LIST OF FIGURES

- 1.1 Overall OMI Revenue Market Share, 2009
- 1.2 OMI Revenue Forecast by Application, 2009-2014
- 2.1 Estimate of Unit Sales of OMI Systems by Company
- 3.1 Visible and Near-Infrared Wavelengths in the Spectrum
- 3.2 Fluorescent Probes
- 3.3 Commercial Setup for the IVIS Spectrum, a Combined Bioluminescence/Fluorescence System
- 3.4 Simultaneous Quantification of Five Mixing Agents
- 3.5 Commercial Setup for Fluorescence Molecular Tomography
- 4.1 Comparing IVIS Imaging to Conventional Detection
- 4.2 Stages of the Drug Development Process
- 4.3 3D Image of a Lung Tumor Using Bioluminescence
- 4.4 ART' s SoftScan Breast Imager
- 4.5 Imaging the Human Lymphatic System
- 5.1 OMI Revenue Forecast by Application, 2009-2014
- 5.2 Overall OMI Revenue Share, 2009
- 5.3 Preclinical Imaging System Revenue Share, 2009
- 5.4 New Companies Will Enter the Market by Mid-Decade
- 5.5 The Combination of OMI Agents and Imaging Systems Provides Many Options for Clinical Use
- 5.6 New Cancer Cases per Year through 2030
- 5.7 The SoftScan Breast Imager
- 5.8 The Imaging Agent Development Process
- 6.1 OMI Timeline

## LIST OF TABLES

- 3.1 Wavelength and Associated Tissue Penetration
- 4.1 Selected Target Molecules and Their Related Disease Processes
- 4.2 Selected Clinical Trials
- 5.1 OMI Forecast by Application - Units, Prices, and Revenues, 2009-2014
- 5.2 Comparison of Cost per Scan and Insurance Reimbursement by Imaging Modality
- 6.1 Geographic Placement of OMI Companies
- 6.2 Preclinical Imaging Systems and Agents

[▲ Back to Top](#)

**Please inform me when related publications are released**



[➔](#)  [Subscribe InfoWatch](#)

| [FAQ](#) | [About Us](#) | [Policies](#) | [Site Map](#) |

US: +1-860-674-8796 (Int'l) +1-866-353-3335 (Toll Free) | EU: +32-2-535-7543

The vertical markets research portal

© 1997-2010, Global Information, Inc. All rights reserved.